Acumen Pharmaceuticals, Inc. (ABOS) intrinsic value & 10-year financials
Acumen Pharmaceuticals, Inc. (ABOS) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.69
- Market cap
- $102.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -42.1%
- Free cash flow (FY2025)
- -$115.6M
ABOS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$121.3M | -$2.00 | -$115.6M | — | -110.9% |
| FY2024 | — | -$102.3M | -$1.71 | -$86.2M | — | -56.2% |
| FY2023 | — | -$52.4M | -$1.08 | -$43.1M | — | -42.3% |
| FY2022 | — | -$42.9M | -$1.06 | -$35.3M | — | -77.1% |
| FY2021 | — | -$100.6M | -$2.51 | -$18.0M | — | -19.0% |
| FY2020 | — | -$7.3M | — | — | — | 52.7% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Acumen Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Acumen Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.1% ROIC.
Acumen Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Acumen Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.